Anebulo Pharmaceuticals, Inc. announced the appointment of Bimal Shah to its Board of Directors. Mr. Shah will serve as a member of the board?s audit and compensation committees. Mr. Shah is Chief Financial Officer of Corium LLC, a Boston-based commercial-stage biopharmaceutical company, where he has been employed since August 2022.

Prior to joining Corium, he served as Senior Vice President, Corporate Finance and Strategy, for Sumitovant Biopharma, a wholly owned subsidiary of Sumitomo Pharmaceuticals, one of Japan's largest pharmaceutical companies. Mr. Shah previously held business development, finance, and strategic commercial roles at Spectrum Pharmaceuticals and Genentech (part of Roche). He also worked in the financial sector at Goldman Sachs, J.P. Morgan, and Warburg Pincus, where he focused on the broader life sciences and healthcare sectors and was responsible for executing a wide range of deal transactions, including financings, investments, acquisitions, and alliances.

Mr. Shah received his Master's in Business Administration, Master of Arts in International Policy Studies and Bachelor's in Economics from Stanford University.